Health Professional Exposure Assessment to Covid-19

NCT04429724 | Completed

• 1 other identifier: RIPH_2020_8
• Study Type: interventional
• Target: 2,129
• Locations: 1 country
• Sites: 4

Brief Summary

Understanding the SARS-Cov2 epidemic is a major public health issue, both in the community and in the hospital sector. Because of their central position in the management of patients infected with COVID-19, hospital staff may be considered at high risk of infection. The development of serological tests makes it possible to reliably document a contamination, symptomatic or not, that is more than 3 weeks old. These tests, combined with clinical questioning of the symptoms, make it possible to determine the proportion of asymptomatic infections whose impact in the transmission of this disease appears to be major. The duration of the presence of the antibodies that are hoped to neutralize after infection with CoV2-SARS remains uncertain. Documenting the evolution of antibody levels and their monitoring in a population at high risk of re-exposure to CoV2-SARS is a major issue in understanding this disease and in assessing the risk of infection among healthcare workers.

Conditions

COVID-19

Outcome Measures

Primary Outcomes (1)

• Number of contaminated personnel

  Number of contaminated personnel by occupational category and department on day 1.

  day 1

Secondary Outcomes (6)

• Number of contaminated personnel

  month 3

• Number of contaminated personnel

  month 6

• Number of symptomatic staff by occupational category and service

  month 3

• Number of symptomatic staff by occupational category and service

  month 6

• Number of contaminated personnel with effective protection

  evolution at day 1, month 3 and month 6

Study Arms (1)

health workers at hospital

EXPERIMENTAL

Three blood samples will be taken at day 1, month 3 and month 6. A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.

Diagnostic Test: Diagnostic test Covid-19

Interventions

Diagnostic test Covid-19 DIAGNOSTIC_TEST

Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.

health workers at hospital

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Staff on duty in the health facility
• Eligible to be drawn
• Beneficiary subject affiliated or entitled to a social security scheme

You may not qualify if:

• Minor patient
• Refusal to participate
• Patient under guardianship
• Patient under guardianship

Sponsors & Collaborators

• Tourcoing Hospital: lead

Study Sites (4)

CH Roubaix

Roubaix, France

Location

CH Tourcoing

Tourcoing, France

Location

CH Wasquehal

Wasquehal, France

Location

CH Wattrelos

Wattrelos, France

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• PATOZ Pierre, PharmD

  CH TOURCOING

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 10, 2020
• First Posted: June 12, 2020
• Study Start: July 6, 2020
• Primary Completion: March 16, 2021
• Study Completion: March 16, 2021
• Last Updated: May 10, 2022

Record last verified: 2022-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (4)